Transcript Capabilities Presentation - Rx Communications Group, LLC

Rx Communications Group, LLC
Capabilities Overview
2000 – 2015: Providing award-winning communications counsel
to life sciences and health care companies
ABOUT Rx COMMUNICATIONS
 Specialists in the life science and health
care industries
 Partner-driven -- Senior level counsel on
EVERY account
 Navigate clients through up and down
market cycles, various political health care
agendas and technology trends
ABOUT Rx COMMUNICATIONS
 Experience with private and public
companies – domestic and international
 Focused on what we do best: Investor
Relations and Financial/Science Media
Relations
 Strong Wall Street and media contacts
 Headquartered in New York City; partnered
with Consilium Strategic Communications in
London
PRIVATE COMPANIES
Services for Private Companies
WHY EMBARK ON AN IR/PR
PROGRAM AS A PRIVATE
COMPANY?
 Lay the groundwork for future financings
and eventual IPO
 Assist with partnering activities by building
corporate awareness
 Build awareness of disease indications to
generate product interest
 Align company with reputable bankers
 Become accustomed to working within
disclosure rules i.e., Reg. FD
PROVIDING VALUE TO
PRIVATE COMPANIES
 Develop key messages positioned for
analysts and investors
 Develop collateral materials to tell story
integrating key messages
 Target and facilitate introductions to venture
capitalists and institutional investors
 Target and advise on corporate finance
team
 Target and facilitate introductions to sellside analysts
PROVIDING VALUE TO
PRIVATE COMPANIES
 Build presence on the web
 Review upcoming newsworthy events and
develop story ideas for the media
 Cultivate reporter interest
 Introduce to conference circuit
 Strategically position company news to
optimize impact
 Develop company disclosure policy
ACTIVITIES SURROUNDING
IPO
 Assist in the selection of banking team –
beginning of quiet period
 Press release announcing registration for
offering
 Develop roadshow presentation
 Supplement banker’s list of target
institutions
 Presentation training
ACTIVITIES SURROUNDING
IPO
 “Teach-ins” at banks
 Roadshow
 Press release announcing completion of
IPO
 Create disclosure policy
 Quiet period compliance
PUBLIC COMPANIES
Services for Public Companies
AFTER-MARKET SUPPORT
 Need for continual dialogue with
shareholders
 Ongoing targeting of investors for future
financings
 Increase analyst coverage beyond banking
support
 Fulfill disclosure requirements
 Crisis communications
 Strategic media outreach
GETTING STARTED: FIRST
STEPS
 Strategy session in order to immerse
ourselves in corporate story
 Define key message points
 Understand perceptions existent in the
marketplace
 Create targeted list of sell-side analysts,
venture capitalists and fund managers
GETTING STARTED: FIRST
STEPS
 Review collateral materials
 Create VIP blast e-mail/fax lists
 Develop media lists
 Design action plan
Rx COMMUNICATIONS
CAPABILITIES











Strategic Counsel
Roadshows
Analyst Contact
Investor Targeting
Investment and Industry Conferences
Follow-up and Analysis to Key Events
Press Release Writing
News Conferences/Press Briefings
Video/Radio News Releases
Fact Sheets
Annual Reports
Rx COMMUNICATIONS
CAPABILITIES










Crisis Communications
Mergers and Acquisitions
Positioning Strategy
Perception Audits
Conference Calls
Presentation Training
Placement Strategy
Financial, Trade and Local Media Contacts
Slide Presentations
Web Site Development
THE Rx TEAM
Melody A. Carey, Co-President
 Founded Rx Communications in 2000
 Head of Corporate Communications and
Spokesperson, Schein Pharmaceutical, Inc.
 Director of Investor Relations,
The Multicare Companies, Inc.
 Executive, Noonan/Russo Communications
 Former health care/life sciences investment
banker, Kidder, Peabody & Co.
THE Rx TEAM
Rhonda Chiger, Co-President
 Founded Rx Communications in 2000
 Senior Managing Director, Global
Consulting Practice, Thomson Financial
 Managed Life Sciences departments for
Noonan/Russo and Dewe Rogerson
 Established London office for health care
investor relations firm
 Manager, Investor Relations, American
Stock Exchange
THE Rx TEAM
Eric Goldman, Vice President
 Six years with Rx Communications
 25 years experience in public relations and
as a media relations strategist specializing
in biotechnology, health care, technology
and consumer products
 Senior Director and Vice President at
GlobalFluency
 Handled media relations at Spector &
Associates and Brouillard Communications,
a division of J. Walter Thompson
 Earned 2 Silver Anvil awards for public
relations excellence
THE Rx TEAM
Paula B. Schwartz, Senior Vice President
 Ten years with Rx Communications
 Partner, FRB/Weber Shandwick, oldest and
largest Investor Relations firm in the U.S.
 Vice President, ECOM Consultants, Inc., an
investor relations firm
 Vice President/Director of Investor
Relations Programs, KCS&A Public
Relations, a public relations and investor
relations consultancy
THE Rx TEAM
Steve Silver, Senior Vice President
 Joined Rx Communications in April 2015
 More than15 years of professional
experience as a Wall Street analyst focused
on healthcare and an investor relations
specialist
 Senior Industry Equity Analyst at S&P
Capital IQ, covering Biotechnology and
Healthcare Facilities
 Senior Investor Relations Manager, Anne
McBride Company and Global Consulting
Group (both now part of Grayling)
Rx COMMUNICATIONS
CURRENT CLIENT LIST

Admedus Ltd. (ASX:AHZ)

Alexandria Real Estate Equities, Inc. (NYSE:
ARE)

Alexion Pharmaceuticals Inc. (Nasdaq: ALXN)

Bellerophon Therapeutics LLC (Nasdaq: BLPH)

Bio-Path Holdings, Inc. (Nasdaq: BPTH)

CollPlant (TASE: CLPT)

Intact Medical Corporation (Private)

Ion Beam Applications or IBA (Euronext Brussels:
IBAB)

MAXIMUS, Inc. (NYSE: MMS)
Rx COMMUNICATIONS
CURRENT CLIENT LIST

Nanotherapeutics (Private)

Ophthotech Corporation (Nasdaq: OPHT)

Orexo AB (Nasdaq OMX: ORX and US OTCQX: ORXOY)

Oxford BioMedica plc (LSE: OXB)

PharmAthene, Inc. (NYSE MKT: PIP)

Semler Scientific, Inc. (Nasdaq: SMLR)

Sigma-Tau Pharmaceuticals, Inc. (Private)

StemBioSys, Inc. (Private)

Vigilant Biosciences, Inc. (Private)

Zealand Pharma A/S (Nasdaq: OMX Copenhagen:
ZEAL)
OURx SUCCESSES

Helped to grow Alexion Pharmaceuticals’
institutional shareholder base from 30% in 1996
to approximately 95% today.

Launched not-for-profit Immune Tolerance
Institute resulting in broad coverage in the U.S.
including CBS Radio Network, San Francisco
Business Times and Drug Discovery News.

Garnered coverage for Catalyst Pharmaceutical
Partners’ compound for cocaine addiction.
Placements included cover stories in Newsweek,
Scientific American Mind and NeuroInvestment.
OURx SUCCESSES

Designed and implemented assertive investor
outreach program for PDI which doubled trading
volume and tripled its stock price within nine
months.

Arranged feature coverage focused on Hodgkins
and non-Hodgkins lymphoma for MethylGene
with Genetic Engineering News, Pink Sheet,
BioCentury and Pharmawire

Implemented aggressive IR program for
PharmAthene, Inc. which enabled the company
to obtain coverage from two new sell-side
analysts, garner investments from four new
institutional funds and increase trading volume
by three-fold within nine months.
OURx SUCCESSES

Generated feature articles with Dow Jones
Newswire, BioWorld Today, FierceBiotech for
the TetraLogic Pharmaceuticals Series C
financing.

Devised communications campaign to increase
visibility of Amorcyte’s enriched bone marrow
stem cell therapy by maximizing clinical data
presented at American College of Cardiology
(ACC) conference. Leveraged key opinion
leaders who presented Amorcyte’s data to gain
media coverage, surpassing competitors with
later stage clinical data and larger operating
budgets. News coverage included: Reuters,
CBS Radio Network, Start-Up Magazine &
Pharmawire.
OURx SUCCESSES

Generated news coverage with Dow Jones
Newswire, Wall Street Journal.com, Drug
Discovery & Development for launch of Neovacs
autoimmune disease therapeutics.

Developed compelling key messages and
arranged media interviews surrounding
ZIOPHARM Oncology sarcoma clinical trials
resulting in news coverage from Bloomberg
Television, Reuters Newswire, BusinessWeek,
Associated Press, Wall Street Journal and
Forbes.

Within nine months, re-positioned MAXIMUS
from a business processing company to a health
care services company. Garnered health care
sell-side research coverage from Bank of
America and Citigroup Global Markets.
OURx SUCCESSES
We are pleased to announce that Rx
Communications has been selected by PR Week
as a finalist for
Rx Communications was named
Best Small PR Agency
by League of American Communications Professionals
Boutique PR Agency of the Year
Rx Communications Group was honored with the
Stevie Award for Best Investor Relations Program
for work on behalf of specialty
pharmaceutical company, NexMed, Inc.
OURx SUCCESSES
Rx Communications was honored with the SABRE
Awards Certificate of Excellence for Building a North
American Investor Base for client Syngenta AG.
We are also pleased to share that our work for
ImpactRx has won an Honorable Mention
Award in LACP’s (League of American
Communications Professionals) Publicity
Campaign Competition.
Rx Communications received an honorable Mention
Award from PR News, as part of the PR News Platinum PR
Awards. The award was issued in the
Financial/Investor Relations category, for the company's
work on behalf of Genaissance Pharmaceuticals, Inc.
WHY Rx COMMUNICATIONS?

Specialist industry knowledge and expertise

Personal attention from Rx partners

Decades of experience in strategic counsel and
implementation of financial public relations
programs

Unique niche in working with private companies

Well versed in IPOs, secondary offerings,
PIPEs, venture rounds and mergers and
acquisitions

“The Street” knows and trusts us
For Additional Information:
Rx Communications Group, LLC
555 Madison Avenue
5th Floor
New York, NY 10022
(917) 322-2568
www.RxIR.com